Belgian Medical Equipment Stock News

TINC (ENXTBR:TINC) posts FY 2025 first half results TINC (ENXTBR:TINC) has released its FY 2025 first half numbers, reporting revenue of €32.6 million and EPS of €0.50. Over the recent periods, revenue moved from €34.7 million and EPS of €0.50 in FY 2024 H1 to €37.1 million and EPS of €0.67 in FY 2024 H2, before landing at the current €32.6 million and EPS of €0.50. Investors will be weighing these figures against a backdrop of forecast revenue and earnings growth. With net profit margins...

Syensqo (ENXTBR:SYENS) has signed a multi year contract with Boeing, putting its advanced materials business in focus for investors and drawing fresh attention to the stock’s role in the aerospace supply chain. See our latest analysis for Syensqo. Despite the Boeing contract and other recent updates such as a planned dividend of €1.1340 per share, board changes and a €500,000,000 bond redemption, Syensqo’s short term share price return has been weak, with a 30 day share price return of 38.97%...

D'Ieteren Group (ENXTBR:DIE) has just posted its FY 2025 numbers with first half revenue of about €4.1b and basic EPS of €4.61, backed by trailing 12 month EPS of €8.40 that lines up with reported earnings growth of 17.3% over the past year. The company has seen revenue move from about €4.3b in the first half of 2024 and €3.9b in the second half of 2024 to €4.1b in the first half of 2025. Trailing 12 month net income, excluding extra items, sits at €445m, alongside earnings growth of roughly...

DEME Group (ENXTBR:DEME) has paired its latest full year earnings release with an annual dividend announcement of €3.15 per share, giving investors fresh information on both profitability and shareholder payouts. See our latest analysis for DEME Group. At a share price of €194.4, DEME Group has seen a 36.9% 90 day share price return and a 47.45% one year total shareholder return. This suggests recent momentum has picked up as investors react to the earnings and dividend announcements. If you...

ageas (ENXTBR:AGS) has proposed a total gross cash dividend of €3.75 per share for 2025, a 7% uplift on 2024, which puts income and capital return firmly in focus for shareholders. See our latest analysis for ageas. ageas shares trade at €60.15, with a 90 day share price return of 4.79% contrasting with a softer 30 day share price return decline of 4.83%, while the 1 year total shareholder return of 16.38% and 3 year total shareholder return of 76.19% indicate that long term momentum has been...

Proximus (ENXTBR:PROX) has just released its full year 2025 results, reporting €6,248 million in sales, €6,620 million in revenue, and net income of €398 million, with earnings per share of €1.23. See our latest analysis for Proximus. At a share price of €7.29, Proximus has had a mixed run, with a 9.05% decline in its 1 month share price return and a 4.29% gain over 3 months. Its 1 year total shareholder return of 16.63% contrasts with a 39.98% total shareholder return decline over five...

Cmb.Tech (ENXTBR:CMBT) has drawn investor attention after reporting full year 2025 results, declaring an interim dividend of US$0.16 per share and announcing a Management Board change involving Chief Strategy Officer Benoit Timmermans. See our latest analysis for Cmb.Tech. The share price has pulled back over the past week with a 7 day share price return of a 6.27% decline. However, the 90 day share price return of 37.34% and 1 year total shareholder return of 43.99% point to momentum that...

Syensqo SA has recently reported weaker fourth-quarter and full-year 2025 results, announced an annual dividend of €1.1340 per share for payment on 18 May 2026, redeemed €500,000,000 of 2.750% fixed-rate bonds early, and confirmed several Board changes including appointing Heike van de Kerkhof as independent Chair. These moves combine pressure on profitability with balance sheet reshaping and refreshed governance, giving investors a complex mix of cost, capital allocation and oversight...

Etex (ENXTBR:094124453) FY 2025 results in focus Etex (ENXTBR:094124453) has just posted its FY 2025 numbers, with first half revenue of €1.9b and basic EPS of €1.36, giving investors fresh data on how profits are holding up through the year. The company has seen revenue move from €1.93b in the first half of 2024 to €1.9b in the first half of 2025, while basic EPS shifted from €1.46 to €1.36 over the same period, against a trailing twelve month EPS of €3.03 on revenue of €3.7b. With net...

Why Viohalco’s Latest Earnings Matter for Investors Viohalco (ENXTBR:VIO) just released full year 2025 results, reporting sales of €7,228.9 million and net income of €235.39 million, both higher than the previous year, which can help explain recent investor interest. See our latest analysis for Viohalco. The full year numbers arrive after a mixed run for the shares, with a 1-day share price return of 5.22% at €13.7, a 30-day share price return of 6.70%, and a 1-year total shareholder return...

argenx (ENXTBR:ARGX) is back in focus after reporting its first year of annual operating profitability and sharing positive Phase 3 Vyvgart data in ocular myasthenia gravis, which is sharpening investor attention on its autoimmune portfolio. See our latest analysis for argenx. argenx’s latest scientific updates and its first full year of operating profitability come after a period where the share price has faced a 9.34% 1 month and 17.93% 3 month share price return decline, even as the 1 year...

Why UCB’s latest earnings matter for shareholders UCB (ENXTBR:UCB) has drawn fresh attention after reporting full year 2025 results, with sales of €7,388 million, revenue of €7,741 million and net income of €1,558 million, all higher than the prior year’s figures. See our latest analysis for UCB. The latest full year earnings have arrived alongside a solid run in UCB’s shares, with a 1 year total shareholder return of 52.36% and a 3 year total shareholder return above 200%. The 9.48% year to...

Shurgard Self Storage (ENXTBR:SHUR) caught investor attention after releasing its 2025 results, reporting revenue of €450.85 million and net income of €597.76 million, along with fresh 2026 guidance for 6% to 8% all store revenue growth. See our latest analysis for Shurgard Self Storage. The latest guidance and 2025 results came after a weak patch for the shares, with a 30-day share price return showing a 10.62% decline and a 1-year total shareholder return showing a 9.73% decline. The recent...

Fagron (ENXTBR:FAGR) has completed the acquisition of Vepakum in Latin America. The deal adds a packaging and distribution player to Fagron’s existing portfolio. This transaction expands Fagron’s presence in the Latin American market and introduces a new business vertical. Fagron focuses on pharmaceutical compounding and related services, and Latin America has become an increasingly important region for healthcare suppliers. By bringing Vepakum into the group, ENXTBR:FAGR adds packaging and...

Syensqo (ENXTBR:SYENS) has announced a major reshuffle of its Board of Directors, including the appointment of Heike van de Kerkhof as independent Chair. The previous chair and long serving director is stepping down as part of the changes. A new independent director with extensive industry experience is also joining the Board. For you as an investor, Board changes like these matter because they influence how Syensqo sets priorities, manages risks and oversees management. As a specialty...

Recent share performance and business snapshot Umicore (ENXTBR:UMI) has drawn investor attention after recent share price pressure, with the stock showing a 5.4% decline over the past day and a 15.1% decline over the past month. Over the past 3 months, the shares show a 9.4% total return, while the past year reflects a 108.4% total return. Over a longer horizon, 3 year and 5 year total returns are negative at 41.1% and 60.3% respectively. The company reports revenue of €19.4b and net income...

Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ADAPT OCULUS results for VYVGART in adults with ocular myasthenia gravis. The study met its primary endpoint with statistically significant efficacy in this patient group, which currently has limited treatment options. The data are intended to support regulatory submissions that could extend the existing VYVGART label to include ocular myasthenia gravis. Argenx is pairing these results with a broader push to expand VYVGART indications...

UCB (ENXTBR:UCB) has kicked off FY 2025 with first half revenue of €3.5b and basic EPS of €2.50, following a FY 2024 second half that delivered €3.4b in revenue and basic EPS of €4.51. The company has reported an increase in revenue from €2.8b and basic EPS of €1.10 in the first half of 2024 to the latest €3.5b and €2.50, with trailing 12 month basic EPS of €8.20 on revenue of €7.7b. For investors, that mix of higher recent earnings, stronger trailing profitability and a 20.1% net margin...

Azelis Group (ENXTBR:AZE) shares are in focus after the company reported full year 2025 results showing lower sales and net income, alongside a proposed €0.226 per share dividend with a late June ex dividend date. See our latest analysis for Azelis Group. The full year 2025 results and lower proposed dividend come after a year where Azelis Group’s share price return slipped, with a year to date share price return of 10.12% and a 1 year total shareholder return decline of 53.49%, hinting that...

Earnings and dividend announcement set the tone Gimv (ENXTBR:GIMB) has drawn fresh attention after reporting net income of €173.31 million for the nine months to December 31, 2025, and confirming an annual dividend of €1.3650 per share. See our latest analysis for Gimv. The earnings release and dividend confirmation appear to have fed into a positive trend, with Gimv’s 1-day share price return of 1.95% and 7-day share price return of 4.32% lifting the share price to €47.1. The 1-year total...

Wondering if Solvay at €27.88 is offering good value right now, or if the best days are already priced in? This article breaks down what the current share price might be telling you. Over the short term the stock has returned 0.9% in the last 7 days and 7.1% over the past month. The year to date return sits at 2.0% and the 1 year return shows a 4.0% decline, compared with a 3 year return of 50.0% and 5 year return of 63.7%. Recent attention around Solvay has largely focused on how investors...

As European markets experience volatility amid global economic shifts, the pan-European STOXX Europe 600 Index recently hit a new high but ended the week with only a slight gain of 0.09%. This backdrop of fluctuating investor sentiment and economic expansion in key regions like the eurozone presents an intriguing environment for uncovering lesser-known stocks that might offer unique opportunities. In such conditions, identifying stocks with strong fundamentals and potential resilience to...

If you are wondering whether SCR-Sibelco is priced fairly today, you are not alone. The stock often attracts attention from investors trying to work out if they might be overpaying or missing an opportunity. Over the short term, the share price has been mixed, with a 1.3% return over the last 7 days, a 0.8% decline over 30 days, and returns of 12.7% decline year to date and 5.7% decline over the past year, extending to a 10.9% decline over five years. Recent news coverage has mainly focused...

Key Insights Significant control over Biotalys by private equity firms implies that the general public has more power...